Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Assessment of pathological response to therapy using lipid mass spectrometry imaging.

Patterson NH, Alabdulkarim B, Lazaris A, Thomas A, Marcinkiewicz MM, Gao ZH, Vermeulen PB, Chaurand P, Metrakos P.

Sci Rep. 2016 Nov 14;6:36814. doi: 10.1038/srep36814.

2.

Computer-Aided Image Analysis and Fractal Synthesis in the Quantitative Evaluation of Tumor Aggressiveness in Prostate Carcinomas.

Waliszewski P.

Front Oncol. 2016 May 9;6:110. doi: 10.3389/fonc.2016.00110. eCollection 2016.

3.

Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy.

Damani A, Van Hemelrijck M, Wulaningsih W, Crawley D, Cahill D.

World J Urol. 2017 Jan;35(1):35-43. doi: 10.1007/s00345-016-1836-0. Epub 2016 Apr 25.

5.

Subspecialty surgical pathologist's performances as triage pathologists on a telepathology-enabled quality assurance surgical pathology service: A human factors study.

Braunhut BL, Graham AR, Lian F, Webster PD, Krupinski EA, Bhattacharyya AK, Weinstein RS.

J Pathol Inform. 2014 May 26;5(1):18. doi: 10.4103/2153-3539.133142. eCollection 2014.

6.

Gleason scoring at a comprehensive cancer center: what's the difference?

Townsend NC, Ruth K, Al-Saleem T, Horwitz EM, Sobczak M, Uzzo RG, Viterbo R, Buyyounouski MK.

J Natl Compr Canc Netw. 2013 Jul;11(7):812-9.

7.

Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT.

Hum Pathol. 2013 Mar;44(3):310-9. doi: 10.1016/j.humpath.2012.06.001. Epub 2012 Sep 29.

8.

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA.

Cancer. 2012 Dec 15;118(24):6063-71. doi: 10.1002/cncr.27689. Epub 2012 Jun 6.

9.

Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies.

Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, Lawton KA.

Genome Med. 2012 Apr 30;4(4):33.

10.
11.

High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy.

Chaux A, Fajardo DA, Gonzalez-Roibon N, Partin AW, Eisenberger M, DeWeese TL, Netto GJ.

Urology. 2012 Apr;79(4):863-8. doi: 10.1016/j.urology.2011.10.012. Epub 2011 Dec 14.

Supplemental Content

Support Center